CD95 _ FAS
- Known as:
- CD95 _ Fas Cell Surface Death Receptor
- Catalog number:
- 2432
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- CD95 _ FAS
Related genes to: CD95 _ FAS
- Gene:
- FAS NIH gene
- Name:
- Fas cell surface death receptor
- Previous symbol:
- FAS1, APT1, TNFRSF6
- Synonyms:
- CD95, APO-1
- Chromosome:
- 10q23.31
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-25
- Date modifiied:
- 2019-04-23
Related products to: CD95 _ FAS
Related articles to: CD95 _ FAS
- Colorectal cancer remains a leading cause of cancer-related mortality, with resistance to 5-fluorouracil (5-FU) posing a major therapeutic challenge. Thymoquinone (TQ), a bioactive compound derived from , exhibits anticancer activity; however, its system-level effects in colorectal cancer are not fully understood. - Source: PubMed
Publication date: 2026/06/24
Kurowska NataliaKruszniewska-Rajs CelinaStrzałka-Mrozik Barbara - BackgroundRegional anesthesia is central to elective foot and ankle surgery. The popliteal nerve block (PNB) provides extended coverage for midfoot and hindfoot procedures, and ultrasound guidance is postulated to improve block accuracy, safety, and patient comfort.PurposeTo evaluate the clinical effectiveness of ultrasound-guided PNBs in elective foot surgery, focusing on anesthetic success, onset and duration of action, patient tolerance, and postoperative analgesic use.MethodsA retrospective review was conducted of 101 consecutive patients who received ultrasound-guided PNBs in a UK podiatric surgery department between March 2018 and August 2020. Blocks were performed by podiatric surgeons or advanced podiatrists. Outcome measures included onset time of anesthesia (minutes), injection pain assessed using a visual analogue scale (VAS), anesthetic success (adequate anesthesia without top-up), anesthetic failure (complete, tibial, or common peroneal), duration of anesthesia (hours until return of normal sensation), and postoperative analgesic use (days). Descriptive analysis was performed.ResultsThe mean onset time of anesthesia was 21.8 ± 12.2 minutes, and the mean duration was 24.9 ± 11.9 hours. Anesthetic success was achieved in 94 of 101 cases (93.1%), with 7 failures (6.9%) managed using supplementary ankle blocks. The mean VAS pain score during injection was 2.4 ± 1.9 out of 10. Patients required oral analgesia for an average of 4.1 days postoperatively (range: 0-56). No serious complications were reported.ConclusionsUltrasound-guided PNBs provided high success rates, prolonged postoperative analgesia, and good patient tolerance, with no major adverse events. These findings suggest that ultrasound-guided PNBs are a safe and effective regional anesthetic option for elective foot surgery, supporting their role in improving perioperative care and recovery. Prospective comparative studies are recommended to further evaluate their performance against other regional anesthetic techniques.Study DesignRetrospective case series.Level of Evidence4. - Source: PubMed
Publication date: 2026/07/08
Kang Yang SChan TommyWilkinson Antony - BackgroundBone grafting is a commonly used adjunct in foot and ankle surgery to enhance osseous healing in fracture fixation and arthrodesis. Although autologous corticocancellous bone is commonly used, donor site morbidity and limited graft availability have driven the development of allogenic alternatives such as demineralized bone matrix (DBM).FormulationsDemineralized bone matrix is produced through decalcification of donor bone, preserving a collagen-rich scaffold and biologically active proteins that support osteoconduction and osteoinduction. Commercial formulations vary in carrier systems, structural properties, and quality control processes. Products such as DBX (DePuy Synthes/MTF Biologics) and AlloSync (Arthrex) incorporate lot-specific osteoinductivity testing, whereas others including AlloMatrix (Stryker), OrthoBlast II (SeaSpine/Orthofix), and Grafton (Medtronic) use carriers to improve handling. Carrier-free and structural grafts, as well as injectable systems, further expand available options.Clinical ApplicationsThe strongest clinical evidence for DBM exists in fracture fixation, where high union rates have been consistently reported. In arthrodesis procedures, DBM demonstrates union rates comparable to autograft, though without evidence of superiority. Applications in osteochondral lesions of the talus and hallux valgus correction remain less clearly defined, with variable outcomes reported in predominantly small case series. Limited evidence also suggests a potential role in calcaneal bone cysts.ConclusionDemineralized bone matrix is a safe and versatile adjunct that avoids donor site morbidity and provides favorable handling characteristics. However, the current literature is dominated by level III-IV evidence, with no high-quality comparative studies demonstrating superiority over autograft. Demineralized bone matrix is best used in fracture fixation and selective arthrodesis, while further studies are required to define its role in cartilage-related and forefoot procedures. - Source: PubMed
Publication date: 2026/07/08
Tham AlexanderRubin JaredButler James JMontgomery Samuel RMercer Nathaniel PLezak Bradley AAlzobi OsamaMojica EdwardCharalambous LefkoKennedy John G - Erythrocyte membrane fatty acids (FAs) reflect medium-term FA status and may capture integrated metabolic profiles beyond individual FAs. Their relationships with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) remain insufficiently characterized. - Source: PubMed
Publication date: 2026/07/08
Chen LianhuiXu YanniZhang JianiLu Pengcheng - Prospective evidence regarding the associations between circulating fatty acids (FAs) and lung cancer risk-particularly regarding their interplay with exposome factors and genetic susceptibility-remains limited. Furthermore, the predictive utility of FAs as biomarkers for lung cancer has not been fully characterized. Therefore, this study aims to evaluate the associations of circulating FAs metabolism with lung cancer risk, focusing on their interactions with smoking and genetic risk profiles, while further assessing their potential as predictive biomarkers. - Source: PubMed
Publication date: 2026/07/08
Liu YunyunLiu QinghanSun TongYang HonghaoMa ZhengLi LiuxinJi ChaoChen HuanhuanXia Yang